IGFBP7 and acute kidney injury: The use of the combination of two new markers, TIMP-2 (tissue inhibitor of metalloproteinase) and IGFBP7 (insulin-like growth factor binding protein), seems to improve the identification of patients at risk of AKI at 12 hours compared with previous biomarkers [16].